Read by QxMD icon Read

interim Pet hodgkin

Sameer Bakhshi, Sainath Bhethanabhotla, Rakesh Kumar, Krishankant Agarwal, Punit Sharma, Sanjay Thulkar, Arun Malhotra, Deepa Dhawan, Sreenivas Vishnubhatla
BACKGROUND: Data about significance of (18)F-FDG positron emission tomography (PET) at interim assessment and end of treatment in pediatric Hodgkin lymphoma (HL) are limited. METHODS: Patients (≤18 years) with HL were prospectively evaluated with contrast-enhanced computed tomography (CECT) and PET combined with low-dose CT(PET-CT) at baseline, post 2 cycles of chemotherapy and post completion of treatment. Revised international working group criteria (RIW) and Deauville (DA) five point-scale for response assessment by PET-CT were used...
October 6, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Maital Bolshinsky, Chadi Nabhan
Prognostication of patients with diffuse large B-cell lymphoma (DLBCL) has improved in the past decade with a variety of clinical, morphologic, molecular, and radiographic methods. Comparable to data on the value of interim positron emission tomography (I-PET) in Hodgkin lymphoma, several retrospective and prospective studies are attempting to assess the value of I-PET scanning in DLBCL patients. In this review, we briefly describe and analyze the various prognostic methods in DLBCL with specific focus on the value of I-PET scanning in this disease...
September 8, 2016: Clinical Lymphoma, Myeloma & Leukemia
Claudio Agostinelli, Andrea Gallamini, Luisa Stracqualursi, Patrizia Agati, Claudio Tripodo, Fabio Fuligni, Maria Teresa Sista, Stefano Fanti, Alberto Biggi, Umberto Vitolo, Luigi Rigacci, Francesco Merli, Caterina Patti, Alessandra Romano, Alessandro Levis, Livio Trentin, Caterina Stelitano, Anna Borra, Pier Paolo Piccaluga, Stephen Hamilton-Dutoit, Peter Kamper, Jan Maciej Zaucha, Bogdan Małkowski, Waldemar Kulikowski, Joanna Tajer, Edyta Subocz, Justyna Rybka, Christian Steidl, Alessandro Broccoli, Lisa Argnani, Randy D Gascoyne, Francesco d'Amore, Pier Luigi Zinzani, Stefano A Pileri
BACKGROUND: Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease. METHODS: We enrolled 208 patients with classical Hodgkin's lymphoma and treated with ABVD (training set), from Jan 1, 2002, to Dec 31, 2009, and validated the results in a fully matched independent cohort of 102 patients with classical Hodgkin's lymphoma (validation set), enrolled from Jan 1, 2008, to Dec 31, 2012...
October 2016: Lancet Haematology
Michel Meignan
No abstract text is available yet for this article.
October 2016: Lancet Haematology
Charles Mesguich, Anne-Laure Cazeau, Krimo Bouabdallah, Pierre Soubeyran, Martine Guyot, Noël Milpied, Laurence Bordenave, Elif Hindié
We examined the outcome of a cohort of patients with Hodgkin lymphoma (HL) in order to assess if fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) at the end of treatment (end-PET) can be omitted when the interim PET (int-PET) is negative. Seventy-six ABVD(adriamycin, bleomycin, vinblastine, dacarbazine)-treated patients were retrospectively included. No change in treatment was made on the basis of int-PET results. Suspicious foci on end-PET received biopsy confirmation whenever possible...
August 19, 2016: British Journal of Haematology
Yan-Fen Li, Hai-Yan Zhu
Outstanding progress has been achieved in the treatment of Hodgkin's lymphoma in recent years, most of patients can be cured by using modern therapy. However, more and more attentions have been paid on treatment-related complications, the current treatment strategies are focusing on further improving treatment efficacy, while reducing treatment-related toxicity. It is still to be determined whether interim PET imaging could directly judge the therapeutic response so as to make the individualized treatment programs for the patients, for instance through intensifying or abbreviating chemotherapy regimens and/or omitting radiotherapy...
August 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
Hugo J A Adams, Thomas C Kwee
Hodgkin lymphoma, even in advanced-stage, is a highly curable malignancy, but treatment is associated with short-term toxicity and long-term side effects. Early predictive markers are required to identify those patients who do not require the full-length standard therapy (and thus qualify for therapy de-escalation) and those patients who will not be cured by standard therapy (and thus qualify for therapy escalation). Multiple trials have assessed the value of (18) F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after a few cycles of chemotherapy (also known as "interim FDG-PET") in predicting outcome in advanced-stage Hodgkin lymphoma...
August 16, 2016: European Journal of Haematology
Hugo J A Adams, Thomas C Kwee
No abstract text is available yet for this article.
August 5, 2016: Nuclear Medicine Communications
Theodoros P Vassilakopoulos, Peter W M Johnson
There is now good evidence that the escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) is more effective in controlling advanced-stage Hodgkin lymphoma (HL) than the widely used ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine), but the extra efficacy comes at the expense of both short- and long-term toxicity, and there is debate as to whether overall survival is affected. Baseline prognostic factors have proven of limited utility for determining which patients require more intensive therapy and recent studies have sought to use interim fluoro-deoxyglucose positron emission tomography (FDG-PET) evaluation as a means to guide the modulation of treatment, both upwards and downwards in intensity...
July 2016: Seminars in Hematology
Vít Procházka, Miloslav Klugar, Veronika Bachanova, Jitka Klugarová, Dagmar Tučková, Tomáš Papajík
INTRODUCTION: Hodgkin lymphoma is an effectively treated malignancy, yet 20% of patients relapse or are refractory to front-line treatments with potentially fatal outcomes. Early detection of poor treatment responders is crucial for appropriate application of tailored treatment strategies. Tumour metabolic imaging of Hodgkin lymphoma using visual (qualitative) 18-fluorodeoxyglucose positron emission tomography (FDG-PET) is a gold standard for staging and final outcome assessment, but results gathered during the interim period are less accurate...
2016: BMJ Open
Sven Borchmann, Bastian von Tresckow, Andreas Engert
PURPOSE OF REVIEW: After presenting the current treatment recommendations for early-stage Hodgkin lymphoma, we give an overview on recently published clinical trials in this setting. Furthermore, the potential influence of current trials on the treatment of early-stage Hodgkin lymphoma and integration of newly emerging drugs into treatment protocols will be discussed. RECENT FINDINGS: Trials attempting treatment de-escalation and omission of radiotherapy on the basis of early interim PET-scans have been disappointing so far, but results of some large trials employing this strategy are still awaited...
September 2016: Current Opinion in Oncology
Alexey V Danilov, Hongli Li, Oliver W Press, Ilan Shapira, Lode J Swinnen, Ariela Noy, Erin Reid, Sonali M Smith, Jonathan W Friedberg
No abstract text is available yet for this article.
July 7, 2016: Leukemia & Lymphoma
B Ganeshan, K A Miles, S Babikir, R Shortman, A Afaq, K M Ardeshna, A M Groves, I Kayani
OBJECTIVES: The purpose of this study was to investigate the ability of computed tomography texture analysis (CTTA) to provide additional prognostic information in patients with Hodgkin's lymphoma (HL) and high-grade non-Hodgkin's lymphoma (NHL). METHODS: This retrospective, pilot-study approved by the IRB comprised 45 lymphoma patients undergoing routine 18F-FDG-PET-CT. Progression-free survival (PFS) was determined from clinical follow-up (mean-duration: 40 months; range: 10-62 months)...
July 5, 2016: European Radiology
Peter Johnson, Massimo Federico, Amy Kirkwood, Alexander Fosså, Leanne Berkahn, Angelo Carella, Francesco d'Amore, Gunilla Enblad, Antonella Franceschetto, Michael Fulham, Stefano Luminari, Michael O'Doherty, Pip Patrick, Thomas Roberts, Gamal Sidra, Lindsey Stevens, Paul Smith, Judith Trotman, Zaid Viney, John Radford, Sally Barrington
BACKGROUND: We tested interim positron-emission tomography-computed tomography (PET-CT) as a measure of early response to chemotherapy in order to guide treatment for patients with advanced Hodgkin's lymphoma. METHODS: Patients with newly diagnosed advanced classic Hodgkin's lymphoma underwent a baseline PET-CT scan, received two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy, and then underwent an interim PET-CT scan. Images were centrally reviewed with the use of a 5-point scale for PET findings...
June 23, 2016: New England Journal of Medicine
Renata de Oliveira Costa, Abrahão Hallack Neto, Sheila Siqueira, Luis Alberto de Padua Covas Lage, Henrique M de Paula, Arthur M Coutinho, Juliana Pereira
OBJECTIVE: The aim of this study was to analyze the prognostic value of the interim PET (iPET)-computed tomography (CT) (iPET-CT) after two cycles of immunochemotherapy with the R-CHOP protocol in patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) treated with a curative intent in combination with the neoplastic cell origin defined by Hans's immunohistochemstry algorithm followed in a reference center for cancer treatment in Brazil. MATERIALS AND METHODS: We prospectively evaluated 147 DLBCL patients treated with R-CHOP-21 to assess the value of the International Prognostic Index, iPET-CT, and cell of origin by immunohistochemistry as prognostic markers in the rituximab era...
October 2016: Nuclear Medicine Communications
Ryan C Lynch, Ranjana H Advani
Although patients with advanced-stage classic Hodgkin lymphoma have excellent outcomes with contemporary therapy, the outcomes of patients with refractory disease is suboptimal. Identification of these high-risk patients at diagnosis is challenging as the differences in outcomes using clinical criteria are less marked using current modern therapy. Data suggest that an interim PET-CT may be a powerful tool in risk-stratifying patients. Retrospective studies show that a negative interim PET-CT after two to four cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is predictive of favorable outcome independent of IPS score...
2016: American Society of Clinical Oncology Educational Book
Salvatore Annunziata, Annarosa Cuccaro, Maria Lucia Calcagni, Stefan Hohaus, Alessandro Giordano, Vittoria Rufini
OBJECTIVE: To evaluate the prognostic role of the ratio between target lesion and liver SUVmax (rPET) in patients with Hodgkin lymphoma (HL) undergoing interim FDG-PET/CT and to compare rPET with the 5-point Deauville Score (5p-DS). METHODS: Sixty-eight patients with HL undergoing interim FDG-PET/CT after first courses of chemotherapy were evaluated. The receiver operating characteristic (ROC) approach was applied to identify the optimal cutpoint of rPET with respect to progression free survival (PFS)...
October 2016: Annals of Nuclear Medicine
Oliver W Press, Hongli Li, Heiko Schöder, David J Straus, Craig H Moskowitz, Michael LeBlanc, Lisa M Rimsza, Nancy L Bartlett, Andrew M Evens, Erik S Mittra, Ann S LaCasce, John W Sweetenham, Paul M Barr, Michelle A Fanale, Michael V Knopp, Ariela Noy, Eric D Hsi, James R Cook, Mary Jo Lechowicz, Randy D Gascoyne, John P Leonard, Brad S Kahl, Bruce D Cheson, Richard I Fisher, Jonathan W Friedberg
PURPOSE: Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma. PATIENTS AND METHODS: The Southwest Oncology Group S0816 (Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma) trial enrolled 358 HIV-negative patients between July 1, 2009, and December 2, 2012...
June 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Michael Coyle, Lale Kostakoglu, Andrew M Evens
(18)F-fluorodeoxyglucose positron emission tomography with (FDG-PET) has a well-established role in the pre- and post-treatment staging of Hodgkin lymphoma (HL), however its use as a predictive therapeutic tool via responded-adapted therapy continues to evolve. There have been a multitude of retrospective and noncontrolled clinical studies showing that early (or interim) FDG-PET is highly prognostic in HL, particularly in the advanced-stage setting. Response-adapted treatment approaches in HL are attempting to diminish toxicity for low-risk patients by minimizing therapy, and conversely, intensify treatment for high-risk patients...
April 2016: Therapeutic Advances in Hematology
Kathryn S Milks, Thomas W McLean, Evelyn Y Anthony
BACKGROUND: Primary pediatric bone lymphoma is a rare form of non-Hodgkin lymphoma. Unlike nodal forms of lymphoma, imaging abnormalities in lymphoma of bone do not resolve rapidly in conjunction with treatment and radiologic findings can remain abnormal for years, making it difficult to evaluate treatment response. OBJECTIVE: To evaluate the utility of imaging in assessment of patients with primary pediatric bone lymphoma. MATERIALS AND METHODS: At our institution between 2004 and 2013, six cases of pathology-proven primary pediatric bone lymphoma were diagnosed...
July 2016: Pediatric Radiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"